GMAB News and Press, Genmab A/S From 05/05/21

Genmab A/S (GMAB): Q1 GAAP EPS of DKK16.61.Revenue of DKK1.58B (+77.1% Y/Y)Press Release For further details see: Genmab A/S reports Q1 results

Genmab (GMAB) reports worldwide Darzalex (daratumumab) net sales of $1,365M in Q1 2021.U.S. sales were $691M.Genmab receives royalties on the worldwide net sales of Darzalex under the exclusive license agreement with Janssen Biotech, to develop, manufacture and commercialize daratumumab....

Gainers: [[GLYC]] +3.5%. [[CBAY]] +2.6%. [[KPTI]] +2.6%. [[GMAB]] +2.5%. [[SYRS]] +2.4%.Losers: [[VECT]] -8.1%. [[TCRR]] -2.4%. [[JFIN]] -2.3%. [[CENX]] -2.2%. [[GURE]] -1.8%. For further details see: KPTI, CENX, GMAB and TCRR among after-hours movers

FDA action date is Oct 10, 2021 BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) today announced ...

The fund just received a huge distribution boost, making it more appealing to income-oriented investors. The latest declines in BMEZ also coincide with an attractive discount on the fund. BMEZ is an attractive long-term option in the healthcare space that focuses on new tech - tho...

Genmab (GMAB) announces that the European Commission ((EC)) has granted Novartis (NVS) marketing authorization for the use of Kesimpta (ofatumumab) in the treatment of relapsing forms of multiple sclerosis ((RMS)) in adults. The approval was based on data from the Phase 3 ASCLEPIOS I and...

Halvorsen's 13F portfolio value increased from $27.68B to $36.37B. The number of positions increased from 86 to 96. Viking Global added UnitedHealth, AbCellera Biologics, Walt Disney, and Palo Alto Networks while dropping Analog Devices, CME Group, Comcast, and Exact Sciences. The...

Genmab is collaborating with Seagen to launch tisotumab vedotin in hard to treat cervical cancer. The market potential is below $1bn, but as the first commercial launch of an R&D behemoth, this is a substantial development. In trials, the ADC has shown a better profile than Ke...

The following slide deck was published by Genmab A/S in conjunction with their 2020 Q4 earnings call. For further details see: Genmab A/S 2020 Q4 - Results - Earnings Call Presentation

Image source: The Motley Fool. Genmab A/S (NASDAQ: GMAB) Q4 2020 Earnings Call Feb 23, 2021 , 12:00 p.m. ET Operator Continue reading For further details see: Genmab A/S (GMAB) Q4 2020 Earnings Call Transcript